Idenix Pharmaceuticals, Inc. (IDIX) Announces Declaration Of Senior Party In A Second Patent Interference By The USPTO
12/9/2013 9:28:02 AM
CAMBRIDGE, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the United States Patent and Trademark Office (USPTO) declared a patent interference between Idenix's U.S. Patent 7,608,600 and Gilead Sciences, Inc.'s U.S. Patent Application 11/854,218, both related to the use of certain 2'-methyl, 2'-fluoro nucleoside compounds to treat hepatitis C virus (HCV) infections.
Help employers find you! Check out all the jobs and post your resume.
comments powered by